Is Orforglipron Safe?

Orforglipron has already met the FDA’s threshold for approval in the United States, which reflects the high regulatory standard required for a medicine intended for broad public use. Given its position in the fast-growing weight loss market, that approval indicates the drug was considered to have an acceptable balance of safety, quality and effectiveness for its approved population. 

That said, safety depends on how you get it and how you use it. It should only be supplied through a regulated pharmacy and after assessment by a qualified prescriber.  

In the UK, websites offering orforglipron without proper prescribing checks, without a consultation, or before UK licensing should be treated with caution. Medicines bought from unregulated sellers may be fake, poor quality, the wrong strength, or not the real drug at all.  

Further reading: Where to buy orforglipron in the UK

When prescribed in the correct environment, there is a dose-escalation schedule. With GLP-1 medications, treatment starts low and is increased gradually to help reduce stomach-related side effects.  

Overall, the safety picture is reassuring, but like all prescription medicines, it is not risk-free.

The best way to judge its safety is to look at the size of the clinical trial programme and the type of adverse effects seen.

Orforglipron has now been studied across obesity, weight management, and type 2 diabetes programmes involving thousands of participants.

In the early 36-week obesity study, 272 people were randomised. Average weight loss reached up to 14.7% by week 36. Discontinuation due to adverse effects ranged from about 10% to 17% across the orforglipron groups, and serious adverse events were uncommon, with no clinically relevant difference versus placebo.

In the larger 72-week obesity study in 3,127 adults without diabetes, average weight loss reached 11.1% on the highest dose versus 2.1% with placebo. Discontinuation due to adverse effects was 5.1% at 6 mg, 7.7% at 12 mg and 10.3% at 36 mg, compared with 2.6% on placebo. Serious adverse events were reported in 3.8% to 5.5% of those taking orforglipron, versus 4.9% on placebo, so there was no clear excess signal there.

Type 2 diabetes trials

 In the 72-week obesity study in 1,613 adults with type 2 diabetes, average weight loss reached 9.6% on the highest dose versus 2.5% with placebo. Discontinuation due to adverse effects was 6.1% at 6mg and 10.6% at both 12mg and 36 mg, compared with 4.6% on placebo. Lilly’s topline release described the overall safety profile as consistent with the GLP-1 class, but it did not give a clear public serious-adverse-event breakdown in that summary.  

In the 40-week diabetes study of 559 participants, HbA1c fell by 1.3% to 1.6%, and body weight by up to 7.9%. Discontinuation due to adverse effects was 6% at 3mg, 4% at 12mg and 8% at 36mg, compared with 1% on placebo. Again, the public summary did not provide a full serious-adverse-event count, but described the overall safety profile as consistent with injectable GLP-1 medicines.  

In the head-to-head 52-week diabetes study of 1,698 participants, HbA1c fell by up to 2.2% and body weight by up to 9.2%. Discontinuation due to adverse effects was 8.7% at 12mg and 9.7% at 36mg, compared with 4.5% and 4.9% on oral semaglutide.

Other trials

Orforglipron is also being studied in other obesity-related conditions, including weight maintenance after injectable treatment, obstructive sleep apnoea, hypertension, knee osteoarthritis, stress urinary incontinence, and cardiovascular or renal outcomes.  

Lilly has reported positive results in a 52-week phase 3 study in 376 participants, where orforglipron met the primary and key secondary endpoints for maintaining weight loss. For several of the other ongoing programmes, participant recruitment is underway or trials are still running, so full efficacy and safety outcomes are not yet available publicly.  

Side effects are not unusual with GLP-1 medicines. In most people, the common ones are stomach-related, tend to be mild to moderate, and are often worst when starting treatment or stepping up the dose.  

Common side effects

The most common side effects:  

• nausea
• constipation
• diarrhoea
• vomiting
• indigestion (dyspepsia)
• abdominal pain
• bloating or abdominal distension  

Serious side effects

 Serious side effects are much less common, but they matter. The FDA label warns about:

• possible thyroid C-cell tumour risk warning, with the medicine contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2
• acute pancreatitis
• severe gastrointestinal reactions
• acute kidney injury, often linked to dehydration from vomiting or diarrhoea
• hypoglycaemia, especially if used with insulin or insulin-stimulating medicines
• serious allergic reactions, including anaphylaxis or angioedema
• gallbladder problems, such as gallstones or cholecystitis
• delayed stomach emptying, which may matter before anaesthesia or deep sedation  

Further reading: Orforglipron side effects

The main risks with orforglipron are usually not because the medicine is “unsafe” in itself, but because it may be unsuitable for a particular person, interact with other treatment, or be used incorrectly.  

That is why a prescriber reviews your medical history, current medicines, pregnancy status, and any red flags before prescribing.  

Your risk may be higher if you:

• take more than prescribed  
• skip the dose-escalation schedule and increase too quickly 
• buy it from an unregulated seller rather than a licensed pharmacy  
• take medicines that may be affected by delayed stomach emptying  
• use insulin or sulfonylureas, which can increase the risk of low blood sugar  
• already have a condition that makes GLP-1 treatment harder to tolerate, such as severe stomach emptying problems  

Because orforglipron is a once-daily tablet, safe use means taking it exactly as directed and not doubling up doses.  

Further reading: Orforglipron dosage guide

Based on the current US prescribing information, orforglipron should not be used in people with:  

• a personal or family history of medullary thyroid carcinoma  
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)  
• a known serious allergy to orforglipron or its ingredients  

It is also not recommended in some situations, including:  

• pregnancy  
• breastfeeding  
• severe gastroparesis  
• situations where dehydration, pancreatitis risk, or medicine absorption issues make treatment less suitable  

To use orforglipron as safely as possible:  

• take it exactly as prescribed  
• follow the dose-escalation schedule  
• do not take more than one tablet a day  
• do not double up after a missed dose  
• buy it only from a regulated pharmacy  
• tell your prescriber about all medicines and supplements you take  
• get medical advice promptly if you develop severe tummy pain, ongoing vomiting, signs of dehydration, or allergic symptoms  
• tell healthcare professionals you are taking it before surgery or sedation  
• use extra contraceptive precautions if advised, because delayed stomach emptying may affect oral contraceptive absorption after starting treatment and after dose increases